Answers are grounded in this paper and cite their sources.
Objectives: Longitudinal visual and imaging outcomes after intravitreal methotrexate (MTX) for vitreoretinal lymphoma (VRL), and baseline factors associated with remission, remain poorly defined. We evaluated the 12-month efficacy and safety of a reduced-intensity induction regimen followed by response-guided continuation therapy. Methods: Seventeen consecutive patients with VRL confirmed by vitreous cytology and flow cytometry received intravitreal MTX (400 μg/0.1 mL) at two centers in Bucharest, Romania, between 2018 and 2023. Visual acuity (VA), vitritis and optical coherence tomography (OCT) findings were assessed at baseline and at 1, 3, 6 and 12 months (Friedman and Cochran’s Q tests). Results: Mean VA improved from 1.22 ± 0.70 to 0.74 ± 0.63 logMAR (χ2 = 30.82, p < 0.001; Kendall’s W = 0.45), with statistically significant improvement from month 6. At the scheduled 12-month assessment, vitritis and retinal infiltrates had resolved (both unadjusted p < 0.001). Sub-RPE lesions and outer retinal hyperreflectivity decreased (both unadjusted p = 0.031), but these comparisons did not meet the Bonferroni-adjusted significance threshold. Outer retinal disorganization and foveal involvement did not change significantly. Fourteen patients (82.4%) achieved complete ocular remission (median, 6 months); three (17.6%) relapsed and regained disease control after retreatment. Keratopathy was the most frequent adverse event (41.2%); no severe complications occurred. Conclusions: This regimen was associated with a high ocular remission rate, progressive visual improvement and a manageable safety profile. Because all 10 patients with central nervous system lymphoma also received systemic therapy and/or radiotherapy, ocular outcomes cannot be attributed solely to intravitreal MTX.
No takes yet. Share an insight, caveat, or question.
Cioboată et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: